KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Goodwill (2016 - 2025)

Historic Goodwill for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Q3 2025 value amounting to $1.8 billion.

  • Jazz Pharmaceuticals' Goodwill rose 126.55% to $1.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 billion, marking a year-over-year increase of 126.55%. This contributed to the annual value of $1.7 billion for FY2024, which is 209.95% down from last year.
  • As of Q3 2025, Jazz Pharmaceuticals' Goodwill stood at $1.8 billion, which was up 126.55% from $1.8 billion recorded in Q2 2025.
  • In the past 5 years, Jazz Pharmaceuticals' Goodwill registered a high of $1.9 billion during Q2 2021, and its lowest value of $938.4 million during Q1 2021.
  • Over the past 5 years, Jazz Pharmaceuticals' median Goodwill value was $1.7 billion (recorded in 2023), while the average stood at $1.7 billion.
  • In the last 5 years, Jazz Pharmaceuticals' Goodwill skyrocketed by 10562.7% in 2021 and then crashed by 1389.05% in 2022.
  • Jazz Pharmaceuticals' Goodwill (Quarter) stood at $1.8 billion in 2021, then fell by 7.38% to $1.7 billion in 2022, then grew by 3.57% to $1.8 billion in 2023, then decreased by 2.1% to $1.7 billion in 2024, then rose by 6.48% to $1.8 billion in 2025.
  • Its Goodwill was $1.8 billion in Q3 2025, compared to $1.8 billion in Q2 2025 and $1.8 billion in Q1 2025.